Table 1 Patient and transplant characteristics
sCBT (n = 172) | dCBT (n = 362) | P valuea | |
|---|---|---|---|
Median patient age, months (range) | 50 (18–68) | 52 (18–76) | 0.17 |
Median follow-up, months (range) | 54 (1–118) | 34 (2–98) | <0.001 |
Year of transplantation, median (range) | 2008 (2004–2014) | 2010 (2005–2014) | <0.001 |
Recipient sex M, no. (%) | 71 (41) | 201 (56) | 0.002 |
Recipient weight, median (range) | 64 | 70 | <0.001 |
Time from diagnosis to CBT (months), median (range) | |||
CR1 | 6 (3–70) | 6 (2–147) | 0. 7 |
CR2 | 22 (4–95) | 22 (6–209) | 0.7 |
Disease, no. (%) | |||
Acute myeloid leukemia | 131 (76) | 277 (76) | 0.9 |
Acute lymphoblastic leukemia | 41 (24) | 85 (24) | |
Donor CMV seropositive, no. (%) | 107 (65) | 222 (64) | 0.92 |
Status at transplantation, no. (%) | |||
CR1 | 91 (53) | 207 (57) | 0.6 |
CR2 | 72 (42) | 139 (38) | |
CR3 | 9 (5) | 16 (4) | |
Cytogenetics, no. (%) | 0.85 | ||
Acute myeloid leukemia | |||
Good riskb | 7 (5) | 21 (8) | |
Intermediate riskc | 82 (62) | 172 (62) | |
High riskd | 20 (15) | 33 (12) | |
Not reported/failed | 22 (17) | 51 (18) | |
Acute lymphoblastic leukemia | |||
Intermediate riske | 15 (37) | 31 (36) | |
High riskf | 18 (44) | 38 (45) | |
Not reported/failed | 8 (19) | 16 (19) | |
Conditioning regimen, no. (%) | <0.001 | ||
TCF | 113 (66) | 300 (83) | |
TBF | 19 (11) | 5 (1) | |
TTBF | 9 (5) | 0 | |
FM+/−C | 3 (2) | 12 (3) | |
CF+/−T | 9 (5) | 5 (1) | |
Other | 19 (11) | 38 (10) | |
Missing | 0 | 2 (0.5) | |
Recipient CMV-seronegative, no. (%) | 57 (35) | 123 (36) | 0.9 |
ATG, no. (%) | 61 (37) | 51 (16) | <0.001 |
Postgrafting immunosuppression, no. (%) | |||
CNI + MMF | 121 (70) | 327 (90) | <0.001 |
CNI + Pred | 21 (12) | 4 (1) | |
CNI + Mtx | 10 (6) | 9 (2) | |
CNI alone | 10 (6) | 11 (3) | |
Other | 10 (6) | 11 (3) | |